t
On 27 July 2026, IXICO PLC announced it issued a total of 400,000 share options. These options were awarded to advisors of the Company, following shareholder approval of a non-employee sub-plan on 16 April 2026. The options have an exercise price of £0.01 and vesting criteria over a two-year period.
| Date | 27 Jul 2026 |
| Time | 14:46:49 |
| Category | Miscellaneous |
| ID | 0281O |
IXICO PLC
("IXICO or the "Company")
Share option award
27 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today announced that the Company has issued a total of 400,000 share options.
These options are awarded to advisors of the Company. The award follows the approval of a non-employee sub-plan to the IXICO share option plan by shareholders at the general meeting of the Company on 16 April 2026.
These options have vesting criteria aligned with the services to which the advisors are contracted over a two-year period. The options have an exercise price of £0.01.
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.